Premium
ERSPC: features and preliminary results of France
Author(s) -
Villers A.,
Malavaud B.,
Rebillard X.,
Bataille V.,
Iborra F.
Publication year - 2003
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2003.04392.x
Subject(s) - protocol (science) , prostate specific antigen , randomization , family medicine , test (biology) , medicine , gynecology , national health insurance , medical education , randomized controlled trial , prostate cancer , alternative medicine , environmental health , cancer , pathology , biology , paleontology , population
The specific details of the French national programme are based on the design of a local mass screening programme. Men in the screening group are repeatedly invited by mail to be screened while no information other that the national available guidelines on the use of prostate‐specific antigen (PSA) is offered to the control group. The protocol includes randomization before information and consent. In addition, knowledge of any pre‐existing PSA test is obtained through the health insurance database. This will allow separate analysis, if necessary, between groups with previous PSA testing (low participation rate expected) and without (higher participation rate expected).